Table 2.

Inclusion and exclusion criteria

Inclusion Criteria

● CAD patients with hypertensive LVH who receive PCI.

● Male and female aged 18–70 years.

● Coronary stenosis is greater than 70% before PCI performed, and < 20% after PCI, with no need for other angioplasty.

● Trimetazidine naive.

● Provided informed consent.

Exclusion Criteria

● Utilization of trimetazidine, coenzyme Q10 or other medications which would affect cardiac metabolism.

● Concomitant with other causes for left ventricular hypertrophy, such as aortic constriction, hypertrophic cardiomyopathy and cardiac valvular disease.

● Concomitant with other causes for myocardial ischemia, such as congenital heart disease, rheumatic heart disease, dilated cardiomyopathy.

● Presentation with an acute myocardial infarction.

● Severe liver and kidney dysfunction (hepatic transaminase levels > 3 x ULN, bilirubin > 1.5 x ULN, eGFR < 30 mL/min/1.73m2).

● Heart function defined as New York Heart Association IV, or LVEF < 30%.

● Pregnancy or lactating, or possibility of a future pregnancy.

● History of cancer.

● Life expectancy less than 12 months.

CAD coronary artery disease, LVH left ventricular hypertrophy, PCI percutaneous coronary intervention ULN upper limit of normal range, eGFR estimated glomerular filtration rate, LVEF left ventricular ejection fraction